Axsome Thera (AXSM)

Apr 1, 2025, 7:18 AM EDT - 1 day ago

Axsome's depression treatment fails to meet main goal of late-stage study

Mar 25, 2025, 7:13 AM EDT - 8 days ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 21, 2025, 11:36 AM EDT - 12 days ago

Axsome: The Alzheimer's Agitation Program For AXS-05

Feb 24, 2025, 1:34 PM EST - 5 weeks ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Feb 20, 2025, 8:15 AM EST - 5 weeks ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 18, 2025, 11:12 AM EST - 6 weeks ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:20 PM EST - 7 weeks ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

TEVA

Feb 10, 2025, 12:33 PM EST - 7 weeks ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

TEVA

Jan 31, 2025, 7:00 AM EST - 2 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Jan 30, 2025, 3:55 PM EST - 2 months ago

US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:45 PM EST - 2 months ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Dec 31, 2024, 9:15 AM EST - 3 months ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 8:15 AM EST - 3 months ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Dec 30, 2024, 8:13 AM EST - 3 months ago

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

TSLA

Dec 30, 2024, 7:15 AM EST - 3 months ago

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Dec 30, 2024, 7:00 AM EST - 3 months ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Nov 29, 2024, 10:32 AM EST - 4 months ago

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Nov 27, 2024, 1:23 PM EST - 4 months ago

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Nov 12, 2024, 2:02 PM EST - 5 months ago

Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:17 PM EST - 5 months ago

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Nov 8, 2024, 7:00 AM EST - 5 months ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Oct 29, 2024, 7:00 AM EDT - 5 months ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

Sep 4, 2024, 7:00 AM EDT - 7 months ago

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Aug 21, 2024, 7:00 AM EDT - 8 months ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Aug 6, 2024, 3:45 PM EDT - 8 months ago

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 5, 2024, 11:20 AM EDT - 8 months ago

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 8 months ago

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 23, 2024, 4:06 AM EDT - 9 months ago

Axsome Therapeutics: Lots Of Moving Parts

Jul 22, 2024, 3:06 PM EDT - 9 months ago

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

Jun 5, 2024, 7:35 AM EDT - 10 months ago

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

Jun 4, 2024, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

May 29, 2024, 2:45 PM EDT - 11 months ago

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

ARVN CYTK NTLA NVS PFE REGN VKTX

May 29, 2024, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

May 10, 2024, 4:36 AM EDT - 11 months ago

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 8, 2024, 7:00 AM EDT - 11 months ago

Axsome Therapeutics to Present at Upcoming Investor Conferences

May 6, 2024, 11:55 AM EDT - 11 months ago

Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript

May 6, 2024, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Mar 25, 2024, 6:55 AM EDT - 1 year ago

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Mar 5, 2024, 7:00 AM EST - 1 year ago

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 27, 2024, 7:00 AM EST - 1 year ago

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 20, 2024, 6:47 PM EST - 1 year ago

Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript